Uterine cancer is a general term for malignant tumors that begin in the tissues of the uterus. The umbrella includes cancers that originate in the inner lining, the muscular wall, or the lower cervix. Some discussions treat tumors of the cervix separately because their causes, screening and prevention differ, but all arise from parts of the womb and are important to recognize early. For a basic definition and scope, see more about cancers of uterine tissue: overview of uterine tumors.
Major types and anatomical context
The principal categories of tumors associated with the uterus are:
- Endometrial carcinoma — cancers that develop in the endometrium, the glandular lining of the uterus. This is the most common cancer that begins within the uterine body; see endometrial cancer for details.
- Uterine sarcomas — rarer malignancies arising from the myometrium (muscle) or supporting connective tissue; these tend to behave more aggressively than typical endometrial carcinoma.
- Cervical cancer — arises in the cervix, the lower part of the uterus that opens into the vagina. Because its main cause and prevention strategies are distinct, it is often discussed on its own: cervical cancer.
Understanding basic uterine anatomy—the endometrium, myometrium and cervix—helps clarify why symptoms and treatments vary. For anatomy and tissue descriptions, see related resources: uterus tissue overview.
Risk factors and underlying mechanisms
Risk factors differ by type. Many endometrial cancers are linked to prolonged exposure to estrogen relative to progesterone, as occurs with obesity, certain hormone therapies, early menstruation, late menopause and conditions such as polycystic ovary syndrome (PCOS). Obesity is a major, well-recognized risk factor because adipose tissue alters hormone balance: obesity and uterine risk.
Cervical cancer is strongly associated with persistent infection by high‑risk human papillomavirus (HPV) types; prevention of cervical cancer hinges on HPV vaccination and screening: HPV and cervical cancer. Some uterine sarcomas and other variants have different, less well‑understood causes, and certain inherited conditions (for example, Lynch syndrome) raise risk for endometrial cancer in particular.
Signs, diagnosis and staging
Common presenting features are irregular vaginal bleeding (especially after menopause), abnormal discharge, pelvic pain or a sensation of fullness. Early disease is often asymptomatic, which is why attention to unexpected bleeding is important. Diagnostic evaluation may include a pelvic examination, transvaginal ultrasound, endometrial sampling (biopsy), cervical cytology/HPV testing for cervical lesions, and cross‑sectional imaging when spread is suspected.
Pathology from biopsy determines histologic type and grade; additional tests define the stage, which guides treatment and prognosis.
Treatment approaches
Management depends on tumor type, stage, patient health and fertility considerations. Many early endometrial cancers are cured with surgery—typically hysterectomy with removal of fallopian tubes and ovaries when appropriate—and may require lymph node assessment. More advanced or aggressive tumors often need combined modalities:
- Surgery to remove visible disease.
- Radiation therapy to control local or regional disease.
- Chemotherapy when systemic treatment is indicated.
Hormone therapy (progestins) can be used in selected, hormone‑driven endometrial cancers, sometimes as a fertility‑sparing option for young patients. For tumors with specific molecular features (for example, mismatch‑repair deficiency), newer targeted and immunotherapy approaches may be effective in advanced disease.
Prognosis, prevention and notable distinctions
Prognosis varies: tumors detected while confined to the uterus generally have much better outcomes than those found after spread. Cervical cancer outcomes have improved dramatically in places with effective screening and HPV vaccination. Preventive measures differ by type: routine Pap smear and HPV testing and immunization are central to cervical cancer prevention, while endometrial cancer prevention focuses on managing modifiable risks (weight, diabetes, hormone exposure) and monitoring high‑risk individuals. For practical prevention guidance, consult screening and vaccination resources: HPV prevention and clinical screening summaries at cervical cancer screening.
In clinical practice, distinguishing endometrial carcinoma from uterine sarcoma and from cervical malignancy is important because each has different patterns of spread and treatment priorities. Early recognition of abnormal bleeding and prompt diagnostic evaluation remain the most actionable steps for improving outcomes.